Laminin-511/521 and LN-221 for Reproducible Cardiomyocyte Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating cardiomyocytes from pluripotent stem cells are not chemically defined, animal reagent-free, and lack reproducibility, leading to dedifferentiation and inefficiency in producing cardiomyocyte progenitors and mature cardiomyocytes suitable for regenerative medicine and drug testing.
Innovation Solution
Utilizing a combination of laminin substrates, including LN-521, LN-511, and LN-221, with a chemically defined medium and specific inhibitors, to culture pluripotent stem cells, promoting the formation of cardiomyocyte progenitors and mature cardiomyocytes without animal-derived components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to differentiate cardiomyocytes from pluripotent stem cells, then differentiation can be achieved, but the methods are not chemically defined, rely on animal reagents, and lack reproducibility
Solution Approach 1:
The patent defines specific chemical parameters for the culture medium (including precise concentrations of growth factors, supplements, and inhibitors) and for the laminin substrate composition. By controlling these parameters, the method achieves reproducible differentiation while eliminating animal reagents through chemically defined alternatives.
Solution Approach 2:
The patent extracts and eliminates animal-derived components from the differentiation protocol, replacing them with chemically defined substances. This extraction of animal reagents achieves xeno-free conditions while maintaining differentiation efficiency through carefully selected synthetic alternatives.
2Stability of the object's composition
If conventional differentiation protocols are used, then cardiomyocyte generation is possible, but dedifferentiation occurs and cellular phenotypes are unstable
Solution Approach 1:
The patent incorporates feedback mechanisms through the use of specific growth factor combinations and inhibitors that respond to cellular state changes. The chemically defined medium composition is adjusted to provide feedback signals that maintain cellular phenotype stability throughout the differentiation process, preventing dedifferentiation while ensuring efficient cardiomyocyte generation.
3Adaptability or versatility
If animal reagents are used in stem cell culture, then cell maintenance and differentiation can be achieved, but the methods are not suitable for human therapies and drug testing
Solution Approach 1:
The patent creates a universal, chemically defined culture system that can be applied across multiple purposes: human therapy, drug testing, and mechanistic study. The standardized protocol using defined chemicals and laminin substrates provides multi-functionality, eliminating the need for separate animal-based systems for different applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the controlled generation of cardiomyocyte progenitors and mature cardiomyocytes with stable phenotypes, suitable for regenerative cardiology and drug testing, under reproducible and xeno-free conditions.
Implementation Method 1
The process by which a stem cell changes into a more specialized cell is referred to as differentiation. For example, some differentiated cells include heart cardiomyocyte cells, which are derived from pluripotent human embryonic stem cells (hESCs).
Data Source
AI summary
The present disclosure describes methods of differentiating cardiomyocyte progenitor cells and mature cardiomyocyte cells from pluripotent stem cells. The methods may include differentiating pluripotent stems cells on a substrate including (i) laminin-511 or 521 and (ii) laminin 221. The mature cardiomyocyte cells produced by the method may form a human heart muscle cell line for use in regenerative cardiology.